TACOMA, WA--(Marketwired - Oct 20, 2014) - Revalesio Corporation and Rush University Medical Center's Department of Neurological Sciences published findings from two research studies that demonstrate ...
On Wednesday Revalesio Corporation presented new data at the Alzheimer's Association International Conference that identifies the specific cellular pathways by which Revalesio's lead investigational ...
Company to Highlight Imaging Biomarkers for Cytoprotection and Post Hoc Analysis from Phase 2 RESCUE Clinical Trial; RNS60 Led to Shorter Hospital Stays in Acute Ischemic Stroke Subjects Enrolled ...
TACOMA, Wash.--(BUSINESS WIRE)--Revalesio, a clinical-stage pharmaceutical company developing treatments for neurological diseases, presented the design of its recently launched RESCUE Phase 2 ...
TACOMA, Wash., Feb. 7, 2024 /PRNewswire/ -- Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, announced today topline data from the ...
Lowering of infarct growth -- brain tissue loss -- by 50% in patients treated in less than 12 hours following last known well Lowering of infarct growth correlated with clinically meaningful ...
TACOMA, Wash.--(BUSINESS WIRE)--Revalesio Corporation announced today that research related to the use of RNS60, its novel anti-inflammatory, will be featured in two poster presentations at the Annual ...
TACOMA, Wash., Oct. 16, 2013 /PRNewswire/ -- A paper published in the Journal of Neuroimmune Pharmacology shows that Revalesio's novel therapeutic RNS60 significantly improved biochemical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results